Boston bid for BTG shows dreams can come true
BTG’s string-of-beads tempts Boston Scientific to shell out £3.3bn ($4.2bn) for the UK company.
Congenica aims to turn data into information
Sequencing data is all well and good, but what does it mean?
Fireworks among the small and mid-cap device makers
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.